0001209191-18-026832.txt : 20180430
0001209191-18-026832.hdr.sgml : 20180430
20180430160334
ACCESSION NUMBER: 0001209191-18-026832
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180426
FILED AS OF DATE: 20180430
DATE AS OF CHANGE: 20180430
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SHERWIN STEPHEN A
CENTRAL INDEX KEY: 0001079462
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 18789605
MAIL ADDRESS:
STREET 1: C/O CELL GENESYS, INC.
STREET 2: 500 FORBES BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-04-26
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001079462
SHERWIN STEPHEN A
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
1
0
0
0
Common Stock
2018-04-26
4
M
0
15000
7.05
A
58879
D
Common Stock
2018-04-26
4
F
0
1331
79.44
D
57548
D
Non-Qualified Stock Option
7.05
2018-04-26
4
M
0
15000
7.05
D
2011-06-25
2018-05-25
Common Stock
15000
0
D
The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2011, which, if unexercised would have expired on May 25, 2018. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's 2003 Incentive Stock Plan, as amended. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($7.05) was subtracted from the April 26, 2018 market close price ($79.44), and this net amount ($72.39) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,669 shares to the optionee. The 1,331 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program.
/s/ Darin Lippoldt, Attorney-in-Fact
2018-04-30